40
Participants
Start Date
April 1, 2022
Primary Completion Date
March 1, 2026
Study Completion Date
March 1, 2026
Modified GCN+TTF treatment
The regimen will consist of gemcitabine (G) administered at a dose of 800 mg/m2, cisplatin (C) 30 mg/m2, and protein-bound paclitaxel (N) 150 mg/m2 administered on cycle 1 day 1 and every 2 weeks thereafter and TTF will be administered daily (150kHz 18 hours/day) starting with Cycle 1 Day 1 (dose level 1). One cycle consists of 28 days including 2 chemotherapy treatments (same regimen studied in the PAXG trial: Reni BJC 2016 without capecitabine). After completing 6 cycles, patients will then transition to a maintenance phase of G administered at a dose of 1000 mg/m2 every 2 weeks and daily TTF (150 KHZ 18 hours/day) until progression of disease (POD) per RECIST v1.1.
RECRUITING
Mayo Clinic in Florida, Jacksonville
Lead Sponsor
NovoCure Ltd.
INDUSTRY
Mayo Clinic
OTHER